Brinker Capital Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.89M Sell
11,853
-9
-0.1% -$3.99K 0.05% 344
2026
Q1
$5.3M Sell
11,862
-289
-2% -$135K 0.05% 347
2025
Q4
$5.51M Buy
12,151
+1,803
+17% +$777K 0.04% 399
2025
Q3
$4.05M Sell
10,348
-993
-9% -$415K 0.03% 504
2025
Q2
$5.05M Buy
11,341
+1,768
+18% +$815K 0.04% 387
2025
Q1
$4.64M Buy
9,573
+610
+7% +$284K 0.05% 367
2024
Q4
$3.61M Buy
8,963
+154
+2% +$71.4K 0.04% 428
2024
Q3
$4.1M Sell
8,809
-710
-7% -$341K 0.04% 399
2024
Q2
$4.46M Buy
9,519
+1,133
+14% +$492K 0.05% 343
2024
Q1
$3.51M Sell
8,386
-1,623
-16% -$686K 0.04% 425
2023
Q4
$4.19M Sell
10,009
-485
-5% -$179K 0.05% 344
2023
Q3
$3.65M Sell
10,494
-1,048
-9% -$367K 0.04% 379
2023
Q2
$4.06M Buy
11,542
+662
+6% +$223K 0.04% 374
2023
Q1
$3.43M Buy
10,880
+2,955
+37% +$886K 0.04% 373
2022
Q4
$2.29M Sell
7,925
-1,258
-14% -$383K 0.05% 420
2022
Q3
$2.66M Sell
9,183
-480
-5% -$138K 0.06% 350
2022
Q2
$2.72M Sell
9,663
-3,718
-28% -$995K 0.05% 356
2022
Q1
$3.49M Sell
13,381
-43
-0.3% -$10.2K 0.05% 336
2021
Q4
$2.95M Buy
13,424
+2,301
+21% +$447K 0.04% 426
2021
Q3
$2.24M Hold
11,123
0.04% 521
2021
Q2
$2.24M Buy
11,123
+36
+0.3% +$7.53K 0.03% 574
2021
Q1
$2.38M Sell
11,087
-11,596
-51% -$2.55M 0.04% 458
2020
Q4
$5.36M Buy
22,683
+12,838
+130% +$2.95M 0.08% 285
2020
Q3
$2.68M Buy
+9,845
New +$2.72M 0.05% 382
2020
Q1
Sell
-72
Closed -$16K 750
2019
Q4
$16K Buy
72
+5
+7% +$1.01K ﹤0.01% 528
2019
Q3
$11K Sell
67
-436
-87% -$77.1K ﹤0.01% 569
2019
Q2
$92K Buy
503
+229
+84% +$40K ﹤0.01% 498
2019
Q1
$50K Buy
+274
New +$50.6K ﹤0.01% 475
2016
Q4
Sell
-3
Closed 652
2016
Q3
$0 Buy
+3
New +$284 ﹤0.01% 629
2016
Q1
Sell
-12
Closed -$2K 690
2015
Q4
$2K Buy
12
+3
+33% +$362 ﹤0.01% 475
2015
Q3
$1K Buy
+9
New +$1.16K ﹤0.01% 442

Other funds holding VRTX

Brinker Capital Investments's VRTX Position: Q2 2026 in Review

Brinker Capital Investments reduced its Vertex Pharmaceuticals (VRTX) stake by 0.08% in Q2 2026, selling an estimated $3.99K and leaving 11,853 shares worth $5.89M. The position accounts for 0.05% of the portfolio, ranked #344.

Brinker Capital Investments first reported a position in VRTX in Q3 2015 and has held it in 31 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Brinker Capital Investments held 11,853 shares of Vertex Pharmaceuticals worth $5.89M as of Q2 2026.
  • Brinker Capital Investments sold 9 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.99K.
  • Vertex Pharmaceuticals made up 0.05% of Brinker Capital Investments's portfolio in Q2 2026, its #344 holding.
  • Brinker Capital Investments first reported a position in Vertex Pharmaceuticals in Q3 2015 and has held it in 31 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.